A legal tangle hovers over Novo Nordisk’s diabetes and weightloss drug semaglutide, just weeks ahead of the possible launch of its injectible version Wegovy in India. Semaglutide is the active ingredient in the drug that’s globally popular as Ozempic / Wegovy, and the Danish company making the drug is presently locked in a patent infringement
Eli Lilly (LLY) and Novo Nordisk (NVO) have become hot stocks over the past year thanks to their blockbuster GLP-1 drugs to treat obesity. Over the last year, Lilly and Novo shares are up 72% and 44%, respectively. By market cap, Novo is the largest company in Europe while Lilly ranks eighth among US companies
The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on a bone repair product, Guyoudao, for around half its revenue The company is developing a generic version of the weight-loss drug Semaglutide, which is undergoing